> View other video statements on the amendment of TRIPS In areas where authorised importers are seeking supplies under the system set out in the proposed amendment to the TRIPS Agreement, it is recognised that it is important to respond promptly to these needs, in accordance with the provisions of the proposed amendment to the TRIPS Agreement; (4) Paragraph 11 of the Decision of 30 August 2003 provides that this Decision, including the derogations it grants, is to terminate for each Member on the date on which an amendment to the TRIPS Agreement replacing its provisions takes effect for that Member. On 30 January 2017, the World Trade Organisation (WTO) announced the first amendment to the ad hoc agreement, under the heading wto members, welcoming the entry into force of amendments to facilitate access to medicines. Although the scheme entered into force in 2005, it had to be accepted by two-thirds of the members. After successive delays, this amendment finally came into force in January 2017. It is now time to understand how this change can be effective for the least developed countries, especially for the African countries that constitute the largest number of jurisdictions in this category. Two years later, on 6 December 2005, WTO members agreed to permanently incorporate the 2003 decision to renounce the TRIPS Agreement, subject to the adoption of two-thirds of WTO members. The entry into force of the amendment will form an integral part of the TRIPS Agreement on the protection of public health. Contrary to concerns expressed by some doubts that the use of this option could be politically challenged, the amendment provides certainty that each member can export all pharmaceutical products manufactured under compulsory licence to countries with limited domestic capacities. An amendment to the WTO Agreement on Intellectual Property (TRIPS) entered into force on 23 January 2017. . .